Mitoki (1795-TW) In the 2nd fifty percent of the 12 months, the vital blood cancer drug will be released in the United States, which is predicted to boost once-a-year profits expansion level this yr and stabilize gross profit margin performance.
Lamex’s main operations in the next 50 percent of the calendar year target on US listed anticancer medicines. Thanks to the confidentiality settlement signed with the primary company, shipping and delivery and revenue can’t be disclosed. On the other hand, according to the first value, the US industry dimension is about 400 million US bucks, and shipments will be created in accordance to the deal, a selected share of the quantity.
Seeking forward, Lamex at first expected annual profits growth of 5-10% this calendar year, gross financial gain margin of much more than 50% and working expenditures of 850-900 million yuan for each quarter, with an approaching growth rate. at 10%. or exceed the normal and the gross income margin and functioning expenses will preserve the primary focus on.
Lamex’s next quarter web financial gain soon after tax was 328 million yuan, down 26.5% from the previous quarter and 7.6% from the past calendar year, and net earnings per share was 1.26 yuan in the 1st 50 % of the calendar year, web money was 774 million yuan, down 3.7% calendar year on 12 months, and internet profits for every share was 2.97 yuan.
–
